Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 15.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 286,111 shares of the company’s stock after selling 50,433 shares during the period. Dimensional Fund Advisors LP owned approximately 0.07% of Moderna worth $37,444,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. OLD Second National Bank of Aurora acquired a new stake in shares of Moderna during the first quarter worth $29,000. Sterling Investment Advisors Ltd. lifted its position in Moderna by 380.0% in the first quarter. Sterling Investment Advisors Ltd. now owns 240 shares of the company’s stock valued at $31,000 after purchasing an additional 190 shares during the period. Park Capital Group acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $33,000. Certified Advisory Corp acquired a new stake in shares of Moderna in the 1st quarter valued at approximately $33,000. Finally, Elmwood Wealth Management Inc. acquired a new stake in shares of Moderna in the 1st quarter valued at approximately $33,000. Institutional investors and hedge funds own 51.51% of the company’s stock.

MRNA stock opened at $321.11 on Thursday. The stock has a market capitalization of $128.93 billion, a P/E ratio of 256.89, a PEG ratio of 1.06 and a beta of 1.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.33 and a current ratio of 1.39. The firm’s 50-day moving average price is $213.10. Moderna, Inc. has a 12-month low of $54.21 and a 12-month high of $342.51.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 6th. The company reported $2.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.04 by $0.80. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $2.48 billion. Moderna had a return on equity of 19.76% and a net margin of 21.90%. The company’s revenue for the quarter was up 24112.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.35) EPS. Equities analysts predict that Moderna, Inc. will post 25.19 earnings per share for the current fiscal year.

In related news, CEO Stephane Bancel sold 9,000 shares of the stock in a transaction on Wednesday, July 14th. The stock was sold at an average price of $237.22, for a total value of $2,134,980.00. Following the completion of the sale, the chief executive officer now directly owns 6,215,868 shares in the company, valued at approximately $1,474,528,206.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Juan Andres sold 5,000 shares of the stock in a transaction on Friday, July 16th. The shares were sold at an average price of $276.51, for a total value of $1,382,550.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 370,562 shares of company stock valued at $73,433,611. Corporate insiders own 19.40% of the company’s stock.

MRNA has been the subject of several recent analyst reports. Jefferies Financial Group raised their price objective on shares of Moderna from $170.00 to $250.00 and gave the company a “hold” rating in a research note on Thursday, July 15th. They noted that the move was a valuation call. Chardan Capital reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, July 7th. Morgan Stanley cut their target price on shares of Moderna from $201.00 to $190.00 and set an “equal weight” rating for the company in a research report on Friday, May 7th. Piper Sandler cut their price objective on Moderna from $234.00 to $231.00 and set an “overweight” rating for the company in a research report on Thursday, May 6th. Finally, Zacks Investment Research downgraded shares of Moderna from a “buy” rating to a “hold” rating and set a $330.00 target price for the company. in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $183.75.

Moderna Profile

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Further Reading: What is the FTSE 100 index?

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.